Article
Endocrinology & Metabolism
Katherine R. Tuttle, Adeera Levin, Masaomi Nangaku, Takashi Kadowaki, Rajiv Agarwal, Sibylle J. Hauske, Amelie Elsasser, Ivana Ritter, Dominik Steubl, Christoph Wanner, David C. Wheeler
Summary: This study assessed the safety of empagliflozin in patients with type 2 diabetes and moderate to severe chronic kidney disease. The findings showed that empagliflozin did not raise new safety concerns and may have beneficial effects on the development of hyperkalemia and edema.
Article
Endocrinology & Metabolism
Kent Y. Feng, JingWei Li, Juliana Ianus, Dick de Zeeuw, Greg R. Fulcher, Michael Pfeifer, David R. Matthews, Meg J. Jardine, Vlado Perkovic, Bruce Neal, Kenneth W. Mahaffey
Summary: In the CANVAS program, the most common reasons for hospitalization were cardiac disorders, infections and infestations, and nervous system disorders. Canagliflozin, compared with placebo, reduced the rate of total ACH.
DIABETES OBESITY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Eu Jeong Ku, Dong-Hwa Lee, Hyun Jeong Jeon, Tae Keun Oh
Summary: This study investigated the long-term effectiveness and safety of two SGLT2 inhibitors, empagliflozin and dapagliflozin, in inadequately controlled type 2 diabetes patients. Both drugs showed positive effects on glycemic control and body weight reduction, with empagliflozin group demonstrating better outcomes in weight loss and lipid profiles.
DIABETES RESEARCH AND CLINICAL PRACTICE
(2021)
Article
Cardiac & Cardiovascular Systems
Huan Chen, Yochai Birnbaum, Regina Ye, Hsiu-Chiung Yang, Mandeep Bajaj, Yumei Ye
Summary: SGLT2 inhibitors increase plasma ketone concentrations and may induce ketoacidosis in diabetes patients. Dehydration can precipitate SGLT2 inhibitor-induced ketoacidosis in type-2 diabetes. Dapagliflozin attenuated the development of ketoacidosis and associated signaling pathways in T1DM mice.
CARDIOVASCULAR DRUGS AND THERAPY
(2022)
Article
Cardiac & Cardiovascular Systems
Yuta Suzuki, Hidehiro Kaneko, Akira Okada, Hidetaka Itoh, Satoshi Matsuoka, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Kentaro Kamiya, Atsuhiko Matsunaga, Junya Ako, Koichi Node, Hideo Yasunaga, Issei Komuro
Summary: This study compared the cardiovascular risk differences among individual sodium-glucose cotransporter-2 (SGLT2) inhibitors used for the treatment of diabetes mellitus (DM). The results showed no significant differences in the risks of developing heart failure, myocardial infarction, angina pectoris, stroke, and atrial fibrillation among different SGLT2 inhibitors.
CARDIOVASCULAR DIABETOLOGY
(2022)
Article
Pharmacology & Pharmacy
Sjoukje van Der Hoek, Antoon T. M. Willemsen, Ton Visser, Andre Heeres, Douwe J. Mulder, Reinoud P. H. Bokkers, Riemer H. J. A. Slart, Philip H. Elsinga, Hiddo J. L. Heerspink, Jasper Stevens
Summary: SGLT2 inhibitors reduce cardiovascular and kidney risks, but there is individual variation in response. The use of [F-18]canagliflozin PET imaging in this study helped determine the association between clinical canagliflozin doses and SGLT2 occupancy.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Endocrinology & Metabolism
Kirsten Thiele, Matthias Rau, Niels-Ulrik K. Hartmann, Julia Moellmann, Joachim Jankowski, Michael Boehm, Andras P. Keszei, Nikolaus Marx, Michael Lehrke
Summary: SGLT2 inhibitors have been shown to reduce hospitalization for heart failure and cardiovascular mortality, for both patients with and without type 2 diabetes mellitus. These agents have been found to increase haemoglobin and haematocrit levels, which may be a predictor of their cardiovascular benefits.
DIABETES OBESITY & METABOLISM
(2021)
Article
Medicine, Research & Experimental
Lawrence Blonde, Charmi Patel, Bingcao Wu, Yen-Wen Chen, Christopher D. Pericone, Brahim Bookhart
Summary: This study compared the real-world glycemic effectiveness of different SGLT2 inhibitors in individuals with T2DM. Results showed that canagliflozin had similar outcomes to empagliflozin, but was more effective than dapagliflozin in helping patients achieve HbA1c < 8.0%.
ADVANCES IN THERAPY
(2021)
Article
Endocrinology & Metabolism
Jie Yu, Arianne N. Sweeting, Chris Gianacas, Lauren Houston, Vivian Lee, Robert A. Fletcher, Vlado Perkovic, Qiang Li, Brendon L. Neuen, Otavio Berwanger, Hiddo J. L. Heerspink, Dick de Zeeuw, Clare Arnott
Summary: This study assessed the effects of canagliflozin on clinical outcomes and intermediate markers in patients with different BMI categories. The findings showed that canagliflozin reduced the risk of major adverse cardiovascular events and renal outcomes, with no differences in treatment effect across BMI subgroups. However, the effects of canagliflozin on body weight and blood pressure varied among different BMI subgroups.
DIABETES OBESITY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Michelle L. O'Donoghue, Eri T. Kato, Ofri Mosenzon, Sabina A. Murphy, Avivit Cahn, Marisol Herrera, Tsvetalina Tankova, Alena Smahelova, Piera Merlini, Ingrid Gause-Nilsson, Anna Maria Langkilde, Darren K. McGuire, John P. H. Wilding, Larry A. Leiter, Deepak L. Bhatt, Itamar Raz, Marc S. Sabatine, Stephen D. Wiviott
Summary: In this study, it was found that gender did not significantly impact the development of cardiovascular or renal disease in patients with type 2 diabetes treated with dapagliflozin. Furthermore, dapagliflozin showed similar safety and efficacy profiles in women and men.
Article
Cardiac & Cardiovascular Systems
Mikkel Jurgens, Morten Schou, Philip Hasbak, Andreas Kjaer, Emil Wolsk, Bo Zerahn, Mikkel Wiberg, Niels H. Brandt-Jacobsen, Peter Gaede, Peter Rossing, Jens Faber, Silvio E. Inzucchi, Finn Gustafsson, Caroline Kistorp
Summary: Empagliflozin did not improve myocardial flow reserve among patients with type 2 diabetes mellitus and high cardiovascular disease risk. Short-term improvement in MFR does not explain the reduction in cardiovascular events observed.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Article
Cardiac & Cardiovascular Systems
Javed Butler, Milton Packer, Tariq Jamal Siddiqi, Michael Boehm, Martina Brueckmann, James L. Januzzi, Subodh Verma, Ingrid Gergei, Tomoko Iwata, Christoph Wanner, Joao Pedro Ferreira, Stuart J. Pocock, Gerasimos Filippatos, Stefan D. Anker, Faiez Zannad
Summary: This study aimed to evaluate the effect of empagliflozin on patients with chronic kidney disease. It was found through a pooled analysis of EMPEROR-Reduced and EMPEROR-Preserved that empagliflozin can reduce the risk of heart failure and heart failure-related death in patients with different risk categories.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Ashish Sarraju, George Bakris, Christopher P. Cannon, David Cherney, C. V. Damaraju, Gemma A. Figtree, Jagadish Gogate, Tom Greene, Hiddo J. L. Heerspink, James L. Januzzi, Bruce Neal, Meg J. Jardine, Jaime Blais, Mikhail Kosiborod, Adeera Levin, Ildiko Lingvay, Matthew R. Weir, Vlado Perkovic, Kenneth W. Mahaffey
Summary: This study assessed the effects of canagliflozin on cardiovascular outcomes in patients with type 2 diabetes mellitus. The results showed that canagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure, regardless of baseline renal function or level of albuminuria.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2022)
Article
Endocrinology & Metabolism
Odette S. Reifsnider, Anuraag R. Kansal, Pranav K. Gandhi, Lael Cragin, Sarah B. Brand, Egon Pfarr, Kyle Fahrbach, Anastasia Ustyugova
Summary: This study assessed the cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in US adults with T2DM and established CV disease. The model predicted that empagliflozin would dominate canagliflozin, yielding more quality-adjusted life years at a lower cost, and be highly cost-effective compared with dapagliflozin and standard of care using US healthcare costs.
BMJ OPEN DIABETES RESEARCH & CARE
(2021)
Article
Cardiac & Cardiovascular Systems
Yochai Birnbaum, Huan Chen, Dat Tran, Sven Nylander, Yumei Ye
Summary: The combination of dapagliflozin and ticagrelor has additive effects on diabetic nephropathy progression in BTBR ob/ob mice, associated with AMPK activation, reduced NLRP3 inflammasome activation, and increased Akt activation by dapagliflozin.
CARDIOVASCULAR DRUGS AND THERAPY
(2022)